Pilsicainide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pilsicainide
Accession Number
DB12712
Type
Small Molecule
Groups
Investigational
Description

Pilsicainide has been investigated for the treatment of Paroxysmal Atrial Fibrillation.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
AV0X7V6CSE
CAS number
88069-67-4
Weight
Average: 272.392
Monoisotopic: 272.188863401
Chemical Formula
C17H24N2O
InChI Key
BCQTVJKBTWGHCX-UHFFFAOYSA-N
InChI
InChI=1S/C17H24N2O/c1-13-6-3-7-14(2)16(13)18-15(20)12-17-8-4-10-19(17)11-5-9-17/h3,6-7H,4-5,8-12H2,1-2H3,(H,18,20)
IUPAC Name
N-(2,6-dimethylphenyl)-2-(hexahydro-1H-pyrrolizin-7a-yl)ethanimidic acid
SMILES
CC1=CC=CC(C)=C1N=C(O)CC12CCCN1CCC2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Pilsicainide.
AmitriptylineThe risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Amitriptyline.
AmlodipineThe risk or severity of QTc prolongation can be increased when Amlodipine is combined with Pilsicainide.
AnagrelideThe risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Anagrelide.
AtenololPilsicainide may decrease the excretion rate of Atenolol which could result in a higher serum level.
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pilsicainide.
AzithromycinThe risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Azithromycin.
BetaxololThe risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Betaxolol.
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pilsicainide.
BudesonideBudesonide may decrease the excretion rate of Pilsicainide which could result in a higher serum level.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
4820
PubChem Substance
347828910
ChemSpider
4654
BindingDB
50413638
ChEBI
135127
ChEMBL
CHEMBL163238
Wikipedia
Pilsicainide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableUnknown StatusTreatmentParoxysmal Atrial Fibrillation (PAF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0902 mg/mLALOGPS
logP2.75ALOGPS
logP1.16ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)5ChemAxon
pKa (Strongest Basic)10.83ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area35.83 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity84.53 m3·mol-1ChemAxon
Polarizability30.22 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Beta amino acids and derivatives
Alternative Parents
Anilides / m-Xylenes / Pyrrolizidines / N-arylamides / N-alkylpyrrolidines / Trialkylamines / Secondary carboxylic acid amides / Azacyclic compounds / Organopnictogen compounds / Organic oxides
show 2 more
Substituents
Beta amino acid or derivatives / Anilide / M-xylene / Xylene / Pyrrolizidine / N-arylamide / Monocyclic benzene moiety / Benzenoid / N-alkylpyrrolidine / Pyrrolidine
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on October 20, 2016 17:45 / Updated on August 15, 2018 09:59